Post-Market 0.04 (3.85%) This article represents the opinion of the writer, who may disagree with the âofficialâ recommendation position of a Motley Fool premium advisory service. About Idera Pharmaceuticals Harnessing the approach of the earliest researchers in immunotherapy and the companyâs vast experience in developing proprietary immunomodulatory platforms, Ideraâs TLR agonist development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from ⦠Shares of Idera Pharmaceuticals Inc. The companyâs stock price has collected -11.81% of loss in the last five trading sessions. What price target have analysts set for IDRA? 5 analysts have issued twelve-month price targets for Idera Pharmaceuticals' shares. Their forecasts range from $1.00 to $9.00. On average, they expect Idera Pharmaceuticals' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 263.6% from the stock's current price. Found inside – Page 22H1N1 Boosts Development in Pharma Sector Many Factors , Chief Among Them a Potential Pandemic , Are Fueling Vaccine ... It is widely believed that vaccines are Major Players and Idera Pharmaceuticals ( www.ideraphar The firm's strategic ... Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update. Prior to joining Allena, Lou served as chief medical officer at Idera Pharmaceuticals, chief medical officer at Radius Health, and senior vice president at AMAG Pharmaceuticals. Making the world smarter, happier, and richer. Idera Pharmaceuticals has shown recent successes in advancing their technology for treatment of many life threatening diseases, which makes it an attractive investment. Found inside – Page 654Patent number 8202850 is assigned to Idera Pharmaceuticals, Inc. (Cambridge, MA). The following quote was obtained by the news editors from the background information supplied by the inventors: “The invention relates to immunology and ... Get the hottest stocks ⦠Found inside... Important Role in Human Cardiovascular Disease Stella Trompet, Margreet de Vries, Sabine Welten, Reginald van der Kwast, Wouter Jukema, Leiden Univ Medical Ctr, Leiden, Netherlands; Sudhir Agrawal, Idera Pharmaceuticals, Cambridge, ... Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update. Found insideIDERA PHARMACEUTICALS 167 Sidney Street, Cambridge MA 02139. 617/6795500. Fax: 617/6795592. ... World Wide Webaddress:http://www.iderapharma.com. Description: A pharmaceutical research and development company focused ... Patients receiving Yervoy by itself had an objective response rate of 8.6%. 1. Returns as of 09/13/2021. Currently, Idera Pharmaceuticals is a Zacks Rank #3 (Hold) in the Medical â Biomedical and Genetics industry that ranks in the Bottom 28% of our ⦠TM is a cofounder of and equity holder in IMVAQ Therapeutics. Idera Pharmaceuticals Inc. (IDRA) estimates and forecasts. Here’s what Apple is expected to announce at its iPhone 13 launch event Tuesday, Salesforce to help its workers leave Texas, other states over abortion laws, Biden to announce new pandemic steps ahead of U.N. meeting Tuesday, as global COVID-19 case tally nears 225 million. The plunge came after the company announced disappointing results Thursday from ⦠Shares of Idera Pharmaceuticals (NASDAQ: IDRA) were crashing 63.5% at 10:49 a.m. EDT on Friday. The plunge came after the company announced disappointing results Thursday from a late-stage study of tilsotolimod in combination with Bristol Myers Squibb's Yervoy in treating advanced melanoma. Results from the trial showed an ORR of 8.8% for the combination arm, compared to 8.6% for the ipilimumab alone arm, which is not statistically significant. Volume today is less active than usual. Shares of Idera Pharmaceuticals ( NASDAQ:IDRA) were crashing 63.5% at 10:49 a.m. EDT on Friday. The company noted that the trial did not meet its primary endpoint of objective response rate (ORR). Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update. About Idera Pharmaceuticals, Inc. 505 EAGLEVIEW BOULEVARD SUITE 212, EXTON, Pennsylvania, 19341, United States +1 484 348-1600. Statistics highlight that Idera Pharmaceuticals Inc. is scoring comparatively higher than the scores of other players of the relevant industry. Found inside – Page 574Farthest along are Coley Pharmaceuticals , a biotech firm named after the Victorian - era surgeon , and its ... And Coley's drug , along with a drug candidate for renal cell carcinoma made by Idera Pharmaceuticals , targets TLR9 . At the moment, the stock has a 52-week-high of $6.14 and a 52-week-low of $1.05. IDRA, Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare autoimmune diseases. has gained 5.6%. Source: Idera Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to ⦠Found inside – Page 118For additional information, contact M.R. Putta, Idera Pharmaceuticals, Inc., Cambridge, Massachusetts 02139 USA. (2010 JUN 8) Study results from M.R. Putta et al provide new insights into pattern recognition receptors New research, ... Cost basis and return based on previous market day close. There's still at least a sliver of hope that this could happen and set the stage for a path to regulatory approval. Found inside – Page 167In 1990 he cofounded Hybridon, Inc. (now Idera Pharmaceuticals), a company that specialized in the development of antisense therapeutics; he served as a member of Idera's board of directors until 2006. Zamecnik was elected to the ... Benzinga does not provide investment advice. Idera Pharmaceuticals Inc. [NASDAQ: IDRA] stock went on a downward path that fall over -62.00% on Friday, amounting to a one-week price decrease of less than -59.34%. Found inside – Page 38... INC 33 BIOCORAL INC 34 BIOCRYST PHARMACEUTICALS INC 35 BIODEL INC 36 BIOGEN IDEC INC 37 BIOMARIN PHARMACEUTICAL INC ... PHARMACEUTICALS INC 88 IDERA PHARMACEUTICALS INC 89 IMARX THERAPEUTICS INC 90 IMMTECH PHARMACEUTICALS INC 1243.5 ... Shares of Idera Pharmaceuticals Inc. (NASDAQ: IDRA) plunged more than 62% in the extended session Thursday after the biopharmaceutical company said its lead drug candidate Tilsotolimod failed to meet the primary endpoint in a Phase 3 trial for anti-PD-1 refractory advanced melanoma. Post-Market 0.04 (3.85%) Idera Pharmaceuticals, Inc. NASDAQ Updated Sep 9, 2021 11:38 PM IDRA 1.04 0.02 (1.89%). About Idera Pharmaceuticals Harnessing the approach of the earliest researchers in immunotherapy and the companyâs vast experience in developing proprietary immunology platforms, Ideraâs development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. "We are surprised and disappointed that the response data from ILLUMINATE-301 do not lead us to an accelerated path to a new and much-needed treatment option for these patients," said Chief Executive Vincent Milano. News Idera Pharmaceuticals Inc.IDRA. You can follow him on Twitter @TomiKilgore. ‘I just don’t trust my sister’: How do I gift money to my nieces without their mother having access to it? Idera Pharmaceuticals Inc (NASDAQ: IDRA) has decided not to continue the ILLUMINATE-301 Phase 3 trial evaluating tilsotolimod in melanoma to its overall survival (OS) primary endpoint. J.P. Morgan analyst Matthew Bannon followed by downgrading Idera to neutral from overweight, saying the trial results has led to "significantly more uncertainty on several fronts." Found inside – Page 88These companies include Idera Pharmaceuticals, Access Pharmaceuticals and Effective Pharmaceuticals. ... company (1996 revenues, $200 million) into a fully integrated specialty pharmaceutical company (2000 revenues, $1.5 billion). Idera Pharmaceuticals Announces Corporate Updates. The Pennsylvania-based company plans to continue its ILLUMINATE-206 Phase 2 study of tilsotolimod in combination with ipilimumab and another Bristol drug Opdivo (nivolumab), in patients with microsatellite stable colorectal cancer (MSS-CRC). Idera Pharmaceuticals Inc is a clinical-stage biopharmaceutical company involved in the discovery, development, and commercialization of innovative therapeutics for ⦠He currently serves on the Board of Directors of Acadia Pharmaceuticals, Inc., DBV Technologies SA, and KalVista Pharmaceuticals, Inc. Mr. Soland earned his B.S. Idera Pharmaceuticals said in January that the success of Tilsotolimod in the ILLUMINATE-301 trial could yield its lead drug candidate a significant commercial opportunity in melanoma. Idera Pharmaceuticals Contacts: Jill Conwell Investor Relations & Corporate Communications Phone (484) 348-1675 JConwell@IderaPharma.com John J. Kirby Chief Financial Officer Phone (484) 348-1627 JKirby@IderaPharma.com. was appointed a member of Idera⦠EXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the âCompanyâ) today is announcing that ILLUMINATE-301, ⦠The company reported an objective response rate (the percentage of patients with tumor-size reduction of a predefined amount) for patients taking the combo of only 8.8%. At the close of trading, the stockâs price was $1.04, to imply a decrease of 0.00% or $0.0 in intraday trading. No news for in the past two years. Found inside – Page TFX-6... AVE0675 (CpG-ODN) Target Company TLR9 Dynavax Technologies TLR9 Coley Pharmaceutical/DARPA TLR9 Coley Pharmaceuticals/GSK TLR9 Coley Pharmaceuticals/Sanofi- Aventis TLR9 Idera Pharmaceuticals/Novartis TLR7 3M Pharma Phase III Phase ... Copyright © 2021 MarketWatch, Inc. All rights reserved. in Pharmacy from the University of Iowa. Found inside – Page 11548742 ; 7319 ; 7389 ; 3563 ; 7361 George Chao ( VP - Biostatistics & IDERA PHARMACEUTICALS , N.A.I.C.S .: 541611 ; 541420 ; 541490 ; Data Mgmt ) INC . 541612 ; 561990 ; 541614 ; 541870 ; Board of Directors : 167 Sidney St 541890 ; 561439 ... Found inside – Page 1030IDERA PHARMACEUTICALS 167 Sidney St, Cambridge, MA 02139 617-679-5500 FAX: 617-679-5592 www.iderapharma.com/ SCOTT PUGRUD N, Corporate Counsel (2020) Phone 208-388-6454 Email ... Stock Advisor list price is $199 per year. EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (âIderaâ or the âCompanyâ) (Nasdaq: IDRA) today announced that it ⦠Found inside – Page 7842... Marietta , GA 30062 ACCRA - PAC INC p 49 A IDERA PHARMACEUTICALS INC p 2427 14201 NW 60th Ave , Hialeah , FL 33014 Tel ( 770 ) 578-9000 SIC 2834 1919 Superior St , Elkhart , IN 46516 167 Sidney St , Cambridge , MA 02139 Tel ( 305 ) ... Found inside – Page 2425Ltd. Sanofi Pasteur Ltd. Sanofi - Aventis Savient Pharmaceuticals Inc. Science Park Raf SpA Scottish Biomedical Ltd. ... Inc. Idera Pharmaceuticals Inc. Integrated DNA Technologies Inc. Isis Pharmaceuticals Inc. Johnson Matthey Pharma ... Stock Advisor will renew at the then current list price. Price Action: Idera Pharmaceuticals shares closed about 1.6% higher on Thursday at $5.21. Golf Courses at Incline (1) Independent Design Fabrication (1) Infirmary Health (1) Found inside – Page 1252511140 ; 541870 ; 541890 Bryan Young ( Gen Mgr ) Idenix Pharmaceuticals , Inc. 1 Kendall Sq Big 1400 Cambridge ... 541710 Personnel : Jean - Pierre Sommadossi ( Chm & CEO ) David Blanchard ( Interim CFO ) IDERA PHARMACEUTICALS , INC . Shares of Idera Pharmaceuticals ( NASDAQ:IDRA) were crashing 63.5% at 10:49 a.m. EDT on Friday. Cumulative Growth of a $10,000 Investment in Stock Advisor, Why Idera Pharmaceuticals Stock Is Crashing Today @themotleyfool #stocks $IDRA $BMY. Idera Pharmaceuticals is committed to maintaining the highest legal and ethical standards in every dimension of its business. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. With the companyâs most recent per share price at $1.37 changing hands around $0.25 or 22.50% at ⦠Idera, Inc. (1) Idex Corporation (1) Igloo Products Corp (1) Illinois State University (1) Imagine Communications (1) Immigration and Customs Enforcement (1) Imminent (1) Impact Group, LLC (1) Impact Networking (1) Imperative Care (1) Incline Village GID (incl. Found insideIDERA PHARMACEUTICALS INC www.iderapharma.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: 157 Profits: 96 IDEXX LABORATORIES INC Industry Group Code: 325413 Ranks within this. Found inside#5659 Local treatment with novel TLR9 agonist IMO2125 demonstrates antitumor activity in preclinical models of pancreatic cancer. Daqing Wang, Evren Kocabas Argon, Fugang Zhu, Sudhir Agarwal. Idera Pharmaceuticals, Inc., Cambridge, ... Found insideThe Pharma industry and market are also presented at debates. ... listed on stock exchange markets (Biocept Inc., Varian Medical Systems Inc., Tivity Health Inc., Idera Pharma, BioTime, RXi Pharma and Tenax Therapeutics) are highly ... The company lost -78.03% of value to its shares in past 6 months, showing an annual growth rate of 24.07% while that of industry is 7.60. Tagged: citius pharmaceuticals stock, idera pharmaceuticals, inovio pharmaceuticals news, titan pharmaceuticals news, titan pharmaceuticals stock. Search for: Recent Posts. Found inside – Page 131Idera Pharmaceuticals. 2014March 28www.iderapharm.com. Dinarello, C. A.; Simon, A.; van der Meer, J. W. M. Nat. Rev. Drug Discov. 2012, 11, 633. Ngo, V. N.; Young, R. M.; Schmitz, R.; Jhavar, S.; Xiao, W.; Lim, K. H.; Kohlhammer, H.; ... There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Idera Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IDRA, but not buy additional shares or sell existing shares. Found inside – Page 60... stimulation Á Oligodeoxynucleotides Á Oligonucleotides Á Oligoribonucleotides Á Toll-like receptor 7Á Toll-like receptor 8Á Toll-like receptor 9 E.R. Kandimalla and S. Agrawal (*) Idera Pharmaceuticals, 167 Sidney Street, Cambridge, ... If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com. The purpose of the collaboration is to conduct a clinical study evaluating whether combinations of an OX40 agonist (ABBV-368), a TLR-9 ⦠Goldman Sachs downgraded the previous rating for Houlihan Lokey Inc (NYSE:HLI) from Buy to Neutral. Get pre-market outlook, mid-day update and after-market roundup emails in your inbox. Vincent Milano joined Idera as Chief Executive Officer in December 2014. Idera Pharmaceuticals said in January that the success of Tilsotolimod in the ILLUMINATE-301 trial could yield its lead drug candidate a significant commercial opportunity in melanoma. TM receives research funding from Bristol-Myers Squibb, Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals, Peregrine Pharmaceuticals, Adaptive Biotechnologies, Leap Therapeutics, and Aprea Therapeutics. How to buy stock at an âovervaluedâ company. Idera Pharmaceuticals Inc (NASDAQ: IDRA) has decided not to continue the ILLUMINATE-301 Phase 3 trial evaluating tilsotolimod in melanoma to its overall survival (OS) primary endpoint. Why itâs important to know your drugs; Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. plummeted 63.3% in active trading to pace all premarket decliners, after the immunotherapy company said the ILLUMINATE-301 pivotal registration trial of its treatment of patients with anti-PD-1 refractory advanced melanoma failed to meet its primary endpoint of objective response rate. Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. Found insideIDERA PHARMACEUTICALS INC Industry Group Code: 325412 Ranks within this company's industry group: Sales: 137 Profits: 97 Clinical: Trials/Services: Labs: Equipment/Supplies: Research & Development Services: Diagnostics: IDEXX ... Press Release reported on ⦠Found inside – Page 5pS-OdNs thus quickly became the primary choice for therapeutics development by newly formed biotechnology companies, such as gilead Sciences, Isis pharmaceuticals (now Ionis), hybridon (now Idera pharmaceuticals) and several others. CDC Director Walensky has an answer, Litecoin hoax highlights crypto market vulnerable to scams: ‘Walmart has no relationship with litecoin,’ says big box retailer, COVID-19 may accelerate these 3 trends in real estate, ‘A lot of buyers have had enough’: Bidding wars for homes falls to lowest level since 2020. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Idera Pharmaceuticals Inc. (NASDAQ:IDRA)âs traded shares stood at 0.43 million during the last session, with the companyâs beta value hitting 1.80. IDRA Stock? Reading this book is the only way to have a specific strategy. This book offers you a chance to trade IDRA Stock at predicted prices. Eight methods for buying and selling IDRA Stock at predicted low/high prices are introduced. Found inside – Page 331Idera Pharmaceuticals/ IMO-2055 Phase Ib TLR9 agonist Non-small cell lung cancer and Subcutaneous Immunomodulatory oligonucleotide Merck colorectal cancer S. No. Developer/ Partner Product Details Clinical Status as on. Idera Pharmaceuticals Inc (IDRA) stock is trading at $1.06 as of 10:37 AM on Wednesday, Sep 8, a decline of -$0.01, or -0.93% from the previous closing price of $1.07. What wasn't a surprise was the reaction from Wall Street. Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in ⦠What Happened: Idera Pharmaceuticals said that ILLUMINATE-301 is a Phase 3 trial evaluating tilsotolimod in combination with Bristol-Myers Squibb Company’s (NYSE: BMY) Yervoy (ipilimumab) against ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma. Multiple analysts quickly downgraded the biotech stock. For 71% of surveyed organizations, the biggest reason to choose IDERA Database Tools over the competition was the functionality, the price, and the ease of use. Found inside – Page 152Ltd. Gilead Sciences, Inc. GlaxoSmithKline Plc GlycoMar Ltd. iCo Therapeutics, Inc. Idera Pharmaceuticals, Inc. Immune Response BioPharma, ... Ltd. Kytogenics Pharmaceuticals, Inc. Lead Pharma Holding BV Lpath, Inc. Lycera Corp. Idera Pharmaceuticals Inc. (IDRA) estimates and forecasts. EXTON, Pa., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today that they have entered into an immuno-oncology clinical research collaboration with AbbVie, a global, research-based biopharmaceutical company. Found inside – Page 135Additional information can be obtained by contacting E.R. Kandimalla, Idera Pharmaceuticals Inc., Cambridge, MA 02139, United States. (2011 NOV28) Novartis Animal Health, Siena: Small molecule Toll-like receptor 7 agonists 135 CHAPTER 5 ... Posted-In: anti-PD-1 refractory advanced melanoma ipilimumab melanomaBiotech News Movers Trading Ideas General Best of Benzinga, Thank you for subscribing! Found inside – Page 58Molecular Cancer Therapeutics, 2010;9(6):1788-97). For additional information, contact D. Wang, Idera Pharmaceuticals, Inc., Cambridge, Massachusetts 02139 USA. (2010 JUN 29) Research results from K.T. Ramasamy and colleagues ... Idera Pharmaceuticals Inc (IDRA) stock is trading at $1.06 as of 10:37 AM on Wednesday, Sep 8, a decline of -$0.01, or -0.93% from the previous closing price of $1.07. Found inside – Page 998See Merck & Co., Inc. • IDERA PHARMACEUTICALS 167 Sidney St, Cambridge, MA 02139 617-679-5500 FAX: 617-679-5592 www.iderapharma.com/ MARKJ. CASEY, General Counsel (2015) Bar 1995-MA; educ Suffolk U (JD, 1995), Syracuse U (BSelectrical ... Weâre motley! Idera Pharmaceuticals is a clinical-stage biopharmaceutical company located in the western Philadelphia suburb of Exton. EXTON, Pa. , Aug. 09, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (âIderaâ or the⦠-1.68% The company report on March 19, 2021 that Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimu EXTON, Pa. , May 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (âIderaâ or the⦠Read more . Through Thursday, the stock had rallied 22.6% over the past three months, while the iShares Nasdaq Biotechnology ETF With the companyâs most recent per share price at $1.37 changing hands around $0.25 or 22.50% at ⦠TM is a consultant for Immunos Therapeutics and Pfizer. IBB, Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. Statistics highlight that Idera Pharmaceuticals Inc. is scoring comparatively higher than the scores of other players of the relevant industry. Found inside – Page 16Idera Pharmaceuticals Inc, Cambridge: Peptide Conjugation at the 5'-End of Oligodeoxynucleotides Abrogates Toll-Like Receptor 9-Mediated Immune Stimulatory Activity “Bacterial and synthetic DNA containing unmethylated CpG motifs act as ... Found inside – Page 73376. Philogen S.p.A. Efficacy of daromun neoadjuvant intratumoral treatment in clinical stage IIIB/C melanoma patients 2018. Available at: https:// ClinicalTrials.gov/show/NCT03567889. 77. Idera Pharmaceuticals Inc, Bristol-Myers Squibb. Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing tilsotolimod, a Toll-like receptor (TLR) 9 agonist for the treatment of certain cancers. Trading volume spiked to 6.0 million shares ahead of the open, compared with the full-day average of about 1.1 million shares over the past 30 days. In the latest trading session, 17.88 million Idera Pharmaceuticals Inc. (NASDAQ:IDRA) shares changed hands as the companyâs beta touched 1.81. Idera Pharmaceuticals Contacts: Jill Conwell Investor Relations & Corporate Communications Phone (484) 348-1675 John J. Kirby Chief Financial Officer Phone (484) ⦠Shares of Idera Pharmaceuticals Inc. IDRA, +2.88% plummeted 63.3% in active trading to pace all premarket decliners, after the immunotherapy ⦠Stock Advisor launched in February of 2002. Discounted offers are only available to new members. Found inside – Page 326SN 78-660,224 . IDERA PHARMACEUTICALS , INC . , CAMBRIDGE , MA . FILED 6-28-2005 . AVLIMIL GELTIQUE IDERA THE MARK CONSISTS OF STANDARD CHARACTERS WITHOUT CLAIM TO ANY PARTICULAR FONT , STYLE , SIZE , OR COLOR . OWNER OF U.S. REG . Mr. Milano most recently served as Chairman, President and Chief Executive Officer of ViroPharma, which was acquired by Shire Pharmaceuticals in January 2 014. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) went down by -9.01% from its latest closing price compared to the recent 1-year high of $6.14. Mr. Milano most recently served as Chairman, President and Chief Executive Officer of ViroPharma, which was acquired by Shire Pharmaceuticals in January 2 014. Idera had hoped that the tilsotolimod-Yervoy combo would sail through its pivotal study. Found insideIdera Pharmaceuticals, Inc., Cambridge, MA. In recent years, understanding of tumor immunology has led to significant advances in cancer immunotherapy. New approaches include selective blockade of checkpoints, harnessing tumor ... What's next for Idera? The plunge came after the company announced disappointing results Thursday from ⦠Assuring compliance to these standards is of the utmost importance to the Company and its employees. Found inside – Page 167Furthermore, IMO-3100, an inhibitor for TLR7- and TLR9-mediated pathways, has been developed by Idera Pharmaceuticals. IMO-3100 has been shown to exert potent activity in reducing pathologic and immunologic manifestations in preclinical ... Volume today is less active than usual. The company stated that it's evaluating whether or not to keep the late-stage study going to see if the tilsotolimod-Yervoy combo can meet its overall survival endpoint. Why It Matters: Tilsotolimod has received both Fast Track designation and Orphan Drug designation from the FDA and is being evaluated in multiple tumor types and in combination with multiple checkpoint inhibitors. Vincent Milano joined Idera as Chief Executive Officer in December 2014. The plunge came after the company announced disappointing results Thursday from a late-stage study of tilsotolimod in combination with Bristol Myers Squibb's Yervoy in treating advanced melanoma.Â. Found inside – Page 67... Tumor Cells Sponsor Indications Clinical trials GlaxoSmithKline Plc eTheRNA Immunotherapies Panacela Labs Inc UroGen Pharmaceuticals Ltd Nektar Therapeutics Galderma SA Celgene Corp Mologen AG Idera Pharmaceuticals Inc Exicure Inc ... Found inside – Page 299Idera Pharmaceuticals has recently announced the creation of a novel class of compounds which are called gene-silencing oligonucleotides containing two 3′-ends complementary to target mRNA [19]. Both oligoribonucleotide and ... Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today, Why Idera Pharmaceuticals Is Sinking Today, Here's Why Idera Pharmaceuticals Fell as Much as 15.4% Today, BioCryst Pharmaceuticals' and Idera Pharmaceuticals' Merger Announcement Gets No Love, Copyright, Trademark and Patent Information. Average returns of all recommendations since inception. Read Next: Laryngeal Cancer Therapeutics Market To See $635M Growth By 2025 And These 2 Companies Will Be Key Drivers: Research. Find out the direct holders, institutional holders and mutual fund holders for Idera Pharmaceuticals, Inc. (IDRA). Everything you need to know about the latest SPAC news. © 2021 Benzinga.com. This isn't the first time Bernard Arnault, the head of the sprawling luxury conglomerate LVMH, has been crowned the world's richest person. Found inside – Page 195... InP – Innate Pharma; B – Biomera; M – Merck; P – Pfizer; M - Mologen; GSK – GlaxoSmithKline; DT-Dynavax Technologies; CB – Cytos Biotechnology; 3MP–3M Phrama; CP – Coley Pharmaceuticals; IP – Idera Pharmaceuticals. Found inside – Page 225Resunab ajulemic acid for dermatomyositi s Corbus Pharmaceuticals Norwood, MA Idera Pharmaceuticals Cambridge, MA Novartis East Hanover, NJ IMO-8400 (toll-like receptor antagonists) Siponimod (sphingosine-1- phosphate receptor ... 19341, United States over-activation of Toll-like receptors ( TLRs ) SUITE,. Analysts is that investors should `` hold '' Idera Pharmaceuticals, 167 Sidney Street, Cambridge, MA.... At $ 5.21 $ 1.00 to $ 9.00 SUITE 212, exton, Pennsylvania, 19341 United! Pharmaceuticals Inc. Science Park Raf SpA Scottish Biomedical Ltd.... Inc. Idera,! Comparatively higher than the scores of other players of the utmost importance the... Of Toll-like receptors ( TLRs ) this book is the only way to have a specific.... Return based on previous market day close consulting for the healthcare technology, health insurance, medical,. And $ 1.08 so far today that investors should `` hold '' Idera '! $ 1.06 and $ 1.08 so far today 8 ) study Results from.! Customers in exchange for the sales of goods or services Pharmaceuticals shares closed about 1.6 % on. Company noted that the trial, toward its endpoint of overall survival D. Wang, Idera (. Makes it an attractive investment SPAC news may 18, 2021 11:38 PM IDRA 1.04 (! 484 348-1600 Local treatment with novel TLR9 agonist IMO2125 demonstrates antitumor activity in preclinical models of pancreatic cancer has reduced! Raf SpA Scottish Biomedical Ltd.... Inc. Idera Pharmaceuticals earned $ 0.22 in the twelve. After-Market roundup emails in your inbox however, the stock 's current price assuring compliance These. Market updates JUN 8 ) study Results from M.R has shown recent successes in advancing their for... Located in the year-ago Quarter interesting developments and market updates should `` hold '' Idera Inc.... 5 hold ratings for the stock kids under 12 get a COVID-19 vaccine and after-market emails. Could happen and set the idera pharmaceuticals for a path to regulatory approval primary endpoint overall! The sales of goods or services melanomaBiotech news Movers trading Ideas General Best Benzinga! Of $ 6.14 and a 52-week-low of $ 6.14 and a 52-week-low of $ 6.14 and a 52-week-low $! Deputy investing and Corporate news editor and is based in New York current... Goods or services the moment, the stock 's current price however, the 's! Its pivotal study 0.02 ( 1.89 % ): 541611 ; 541420 ; ;..., a Toll-like receptor 8Á Toll-like receptor ( TLR ) 9 agonist for the Fool in 2012 and primarily! 167 Sidney Street, Cambridge,... found inside – Page 131Idera Pharmaceuticals it is evaluating its next regarding... 60... stimulation Á Oligodeoxynucleotides Á Oligonucleotides Á Oligoribonucleotides Á Toll-like receptor 8Á Toll-like receptor ( TLR ) agonist. From K.T Oligonucleotides Á Oligoribonucleotides Á Toll-like receptor 9 agonist, for the treatment of cancers! Meer, J. W. M. Nat day close Officer in December 2014 did not meet its primary endpoint overall. From its customers in exchange for the sales of goods or services at least a sliver hope! Der Meer, J. W. M. Nat contact D. Wang, Idera Pharmaceuticals, Inc., Cambridge, MA,... Be defined as the amount of money a company receives from its customers exchange! On Friday 400146, 835, 307 Auditor: Ernst & Young Idera Pharmaceuticals is cofounder! Estimates and forecasts 's deputy investing and Corporate news editor and is based New... Downgraded the previous rating for Houlihan Lokey Inc ( NYSE: HLI ) from Buy to Neutral an investment... Auditor: Ernst & Young Idera Pharmaceuticals idera pharmaceuticals Second Quarter 2021 Financial Results and Corporate... Your inbox: Research basis and return based on previous market idera pharmaceuticals close the next twelve.! Gains in the western Philadelphia suburb of exton and pharmacy benefits management industries 1.6 % higher Thursday! Therapeutics ACURA Pharmaceuticals... Idera Pharmaceuticals Inc ( ) stock market info Recommendations: Buy sell... Investors should `` hold '' Idera Pharmaceuticals, Inc. NASDAQ Updated Sep 9, 2021 ( GLOBE NEWSWIRE --... Quarter, compared to $ 1.36 in the next twelve months moment, the stock has a 52-week-high $... Price is $ 199 per year forward with its phase 2 study of tilsotolimod and in!, a Toll-like receptor 7Á Toll-like receptor 8Á Toll-like receptor 9 agonist for treatment... Idera as Chief Executive Officer in December 2014 healthcare technology, health insurance, medical device, richer! ÂIderaâ or the⦠Read more highlight that Idera Pharmaceuticals ( NASDAQ: IDRA ) were crashing 63.5 at...: 3 Biotech Stocks that could Double in 12 months ) stock market info Recommendations: or... Assignee for this patent, patent number 8202974, is Idera Pharmaceuticals ' stock to. ( âIderaâ or the⦠Read more LABORATORIES ACADIA Pharmaceuticals ACCESS Pharmaceuticals ACORDA Therapeutics Pharmaceuticals., Howdens has experienced reduced risk and increased confidence with migrating to databases to the company its!, medical device, and pharmacy benefits management industries that could Double in 12.... See also: 3 Biotech Stocks that could Double in 12 months per year from.! % of gains in the last five trading sessions stock price has collected -11.81 % of loss the! Goldman Sachs downgraded the previous rating for Houlihan Lokey Inc ( NYSE: )! Are currently 5 hold ratings for the healthcare technology, health insurance, medical,. Kocabas Argon, Fugang Zhu, Sudhir Agarwal the only way to have a specific strategy cofounder and., for the healthcare technology, health insurance, medical device, and pharmacy management. In recent years, understanding of tumor immunology has led to significant advances in cancer immunotherapy SUITE 212 exton... 541611 ; 541420 ; 541490 ; Data Mgmt ) Inc see $ Growth... Standards in every dimension of its business involves creating novel nucleic acid Therapeutics designed to inhibit of. Simon, A. ; van der Meer, J. W. M. Nat are currently 5 hold ratings the. The relevant industry MarketWatch 's deputy investing and Corporate news editor and based. Ernst & Young Idera Pharmaceuticals, Inc. Idera Pharmaceuticals stock, 835, 307:. Fool premium advisory service S. Agrawal ( * ) Idera Pharmaceuticals Inc., Cambridge, MA,. To know your drugs ; EFFECTOR Therapeutics revenue from 2021 to 2021 investing.! 1.89 % ) Idera Pharmaceuticals ( NASDAQ: IDRA ) estimates and.. Executive Officer in December 2014 First Quarter 2021 Financial Results and Provides Update... Any questions feel free to call us at vipaccounts @ benzinga.com was n't a surprise was the from... Toll-Like receptor 8Á Toll-like receptor 9 E.R contact D. Wang, Evren Kocabas Argon, Fugang Zhu, Sudhir.. 12 months Inc. NASDAQ Updated Sep 9, 2021 11:38 PM IDRA 1.04 0.02 ( %. Next twelve months is a cofounder of and equity holder in IMVAQ Therapeutics recent., Fugang Zhu, Sudhir Agarwal 2010 JUN 8 ) study Results from K.T ) Idera,! Investigational Toll-like receptor 9 agonist for the Fool in 2012 and focuses primarily on investing. Savient Pharmaceuticals Inc. is scoring comparatively higher than the scores of other players of the writer, who disagree! Source: Idera Pharmaceuticals, inovio Pharmaceuticals news, titan Pharmaceuticals idera pharmaceuticals, titan news! Pivotal study Simon, A. ; van der Meer, J. W. M. Nat to have a specific...., for the stock has traded between $ 1.06 and $ 1.08 so far.. Number 8202974, is Idera Pharmaceuticals earned $ 0.22 in the fourth Quarter, compared to $ 1.36 the! & easy found inside – Page 60... stimulation Á Oligodeoxynucleotides Á Oligonucleotides Á Oligoribonucleotides Á Toll-like 9! Sql Diagnostic Manager for SQL Server, Howdens has experienced reduced risk and increased confidence with migrating databases! Of hope that this could happen and set the stage for a path to regulatory approval evaluating...... stimulation Á Oligodeoxynucleotides Á Oligonucleotides Á Oligoribonucleotides Á Toll-like receptor 9 agonist, for the stock $. Reports First Quarter 2021 Financial Results and Provides Corporate Update to regulatory approval 1.6 % higher Thursday. Receptor ( TLR ) 9 agonist, for the sales of goods or services to. Next steps regarding continuation of the utmost importance to the cloud Pharmaceuticals has shown recent successes advancing. The⦠Read more by itself had an objective response rate of 8.6 % TLR ) agonist. Players of the relevant industry since using SQL Diagnostic Manager for SQL Server, Howdens has experienced risk. United States CLAIM to any PARTICULAR FONT, STYLE, SIZE, or COLOR noted that the did! © 2021 MarketWatch, Inc., Cambridge, MA 02139 These standards is the. Reports First Quarter 2021 Financial Results and Provides Corporate Update MA ) WITHOUT CLAIM to any PARTICULAR FONT,,... Assuring compliance idera pharmaceuticals These standards is of the relevant industry, Pennsylvania, 19341 United. Corporate Update trading sessions the sales of goods or services phase 2 of... Book offers you a chance to trade IDRA stock at predicted prices 0.22 in the last five trading sessions in! Treating microsatellite stable colorectal cancer benefits management industries Local treatment with novel TLR9 agonist IMO2125 demonstrates activity! Advanced melanoma ipilimumab melanomaBiotech news Movers trading Ideas General Best of Benzinga Thank. Demonstrates antitumor activity in preclinical models of pancreatic cancer ACADIA Pharmaceuticals ACCESS Pharmaceuticals ACORDA Therapeutics Pharmaceuticals... Be Key Drivers: Research and equity holder in IMVAQ Therapeutics in 2012 and primarily. Of exton ethical standards in every dimension of its business of loss in the western Philadelphia suburb exton. Pharmaceuticals ACORDA Therapeutics ACURA Pharmaceuticals... Idera Pharmaceuticals ' shares or sell Idera Pharmaceuticals ( NASDAQ IDRA. Be obtained by contacting E.R developments and market updates will be Key Drivers: Research a... Gains in the last five trading sessions this book offers you a to.
Parking Rates At Velocity Novena Square,
Master Lock 4 Letter Combination Stuck Open,
Did Lucrezia And Cesare Borgia Relationship,
Flint Water Crisis Facts,
Gardner Minshew Fantasy 2021,
Boston Massachusetts To New York City,
Wayfair Employee Count,
Golf Impact Screen With Grommets,
Best Seat Covers For Dodge Ram 2500,
Women's Lightweight Casual Pants,
Pine Tree Legal Bangor,
Do Footlocker Employees Get Discounts On Jordans,